Brain tumor therapy – A new indication for Hamlet Pharma
Today, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert in the area of neurosurgery, to develop novel technology and methods to treat Central Nervous System (CNS) tumors with Alpha1H.Alpha1H is effective against a range of solid and haematological tumor cells that commonly metastasize to the CNS. Early studies in rats have shown that infusion of HAMLET into the brain markedly delayed the progression of glioblastomas. Glioblastomas are highly invasive and malignant brain tumours with a poor prognosis,